Epithelioid Osteosarcoma — a rare, high-grade osteosarcoma variant distinguished by its predominance of malignant cells with epithelioid morphology (polygonal cells with abundant eosinophilic cytoplasm, vesicular nuclei, and prominent nucleoli) producing osteoid, recognized as a distinct histomorphologic variant within the high-grade osteosarcoma spectrum and notable for its particular diagnostic challenge due to the epithelioid cytomorphology that creates clinical, radiographic, and pathologic confusion with carcinoma metastatic to bone, epithelioid angiosarcoma, and epithelioid hemangioendothelioma — accounting for approximately 1–4% of all osteosarcomas and representing the variant with the highest likelihood of immunohistochemical keratin positivity (documented in 15–40% of cases, contributing to misclassification as metastatic carcinoma), with a peak incidence in the second through fourth decades of life and an age distribution somewhat older than conventional osteosarcoma — presents clinically as pain, swelling, and a destructive bone lesion visible on plain radiographs as a permeative, lytic, or mixed lytic-sclerotic lesion with cortical destruction, soft tissue extension, periosteal reaction, and variable osteoid matrix mineralization; on CT, cortical breakthrough with soft tissue mass and variable matrix mineralization is characteristic; on MRI, epithelioid osteosarcoma demonstrates aggressive intraosseous and extraosseous extent with heterogeneous signal reflecting internal necrosis and variable osteoid production, and the soft tissue component typically enhances heterogeneously; involvement of the pelvis, spine, and proximal extremities may be disproportionately represented relative to conventional osteosarcoma. Pathologically, epithelioid osteosarcoma is characterized by sheets or nests of large polygonal cells with abundant eosinophilic cytoplasm, eccentric nuclei with prominent nucleoli, and variable nuclear pleomorphism, producing lace-like or trabecular osteoid (the defining feature confirming osteoblastic differentiation despite the epithelioid morphology); the differential diagnosis is critically important and broad — metastatic carcinoma (particularly renal cell carcinoma and lung carcinoma, which share polygonal cells with eosinophilic cytoplasm), epithelioid angiosarcoma (vascular channels lined by epithelioid endothelium), epithelioid hemangioendothelioma (chondroid matrix resembling osteoid but CD31/ERG positive), and giant cell-rich osteosarcoma — and immunohistochemical panel interpretation must integrate osteoblastic markers (SATB2 nuclear staining, the most sensitive and specific marker of osteoblastic differentiation, combined with osteocalcin and alkaline phosphatase) with keratin negativity (or focal weak positivity not reaching the diffuse strong expression of carcinoma) and vascular marker negativity (CD31, ERG, CD34 negative to exclude angiosarcoma) to confirm the osteosarcoma diagnosis; molecular profiling of epithelioid osteosarcoma shares the complex genomic instability of conventional osteosarcoma, and next-generation sequencing panels may identify actionable alterations or assist in excluding other diagnoses. Contemporary epithelioid osteosarcoma management follows high-grade osteosarcoma protocols — MAP protocol neoadjuvant chemotherapy (cisplatin, doxorubicin, high-dose methotrexate with leucovorin rescue) for extremity and resectable disease, with wide surgical resection, adjuvant chemotherapy, and 5-year overall survival comparable to conventional high-grade osteosarcoma when accurately diagnosed and treated at high-volume bone sarcoma programs — with the critical caveat that the diagnostic challenge creates real-world delays in appropriate chemotherapy initiation when the epithelioid variant is misclassified as carcinoma and treated with inappropriate systemic therapy.
Epithelioid osteosarcoma technology platforms — whether supporting bone sarcoma programs coordinating MAP protocol neoadjuvant chemotherapy with its time-critical methotrexate level monitoring and leucovorin rescue requirements, pathology and immunohistochemical platforms performing the critical SATB2 immunohistochemistry panel and excluding carcinoma and vascular malignancies through comprehensive immunophenotyping (the diagnostic workup where platform availability at the moment of SATB2 result review determines the entire treatment trajectory), next-generation sequencing platforms providing molecular confirmation and actionable alteration identification, surgical platforms managing wide resection in anatomically variable locations including the pelvis and spine, and long-term surveillance platforms managing serial imaging for local recurrence and pulmonary metastasis — must maintain the availability and performance standards that epithelioid osteosarcoma's diagnostic complexity, chemotherapy intensity, molecular diagnostic requirements, and surgical coordination demand. This guide explains why epithelioid osteosarcoma tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the multimodal management of this high-grade osteosarcoma variant with its characteristic diagnostic pitfall of misclassification as carcinoma.
Why Epithelioid Osteosarcoma Tech Platforms Require Specialized Monitoring Attention
Epithelioid osteosarcoma management is defined by the diagnostic challenge of confirming osteoblastic differentiation in a tumor with epithelioid morphology — where SATB2 immunohistochemistry and the integration of a broad immunophenotypic panel are required to confirm osteosarcoma and exclude carcinoma, angiosarcoma, and hemangioendothelioma — the MAP protocol neoadjuvant chemotherapy complexity requiring serum methotrexate monitoring and time-critical leucovorin rescue, the surgical requirements for wide resection in anatomically variable locations, and the real-world risk of treatment delay when epithelioid morphology with focal keratin positivity leads to inappropriate carcinoma treatment protocols before the correct osteosarcoma diagnosis is established. Technology failures in these domains create disruptions calibrated to the diagnostic accuracy, chemotherapy safety, and surgical precision consequences of a high-grade osteosarcoma where misclassification as carcinoma leads to platinum/taxane or immunotherapy regimens instead of MAP protocol chemotherapy, eliminating the treatment most likely to achieve neoadjuvant response and enable curative-intent surgery.
Pathology and immunohistochemical platforms must confirm SATB2 positivity and prevent carcinoma misclassification. SATB2 immunohistochemistry (the most sensitive osteoblast lineage marker, positive in the majority of epithelioid osteosarcoma cases), the broad exclusionary immunophenotypic panel (keratins, CK7, CK20, TTF-1, PAX8, CD31, ERG, CD34, GATA3, p40, INSM1), and osteoid identification on H&E require reliable immunohistochemistry platform and pathology workflow availability during business hours. Monitor pathology platforms at 1-minute intervals during business hours.
Medical oncology platforms manage time-critical MAP protocol neoadjuvant chemotherapy. High-dose methotrexate with leucovorin rescue, cisplatin, and doxorubicin require serum methotrexate level monitoring at 24, 48, and 72 hours post-infusion, time-critical leucovorin rescue dose escalation, creatinine clearance monitoring, and doxorubicin cardiotoxicity echocardiographic surveillance. Monitor oncology platforms at 1-minute intervals during infusion.
NGS and molecular diagnostic platforms provide molecular confirmation and therapeutic targeting. Next-generation sequencing for copy number alterations and potentially actionable mutations, SATB2 FISH or copy number assessment, and molecular exclusion of fusion genes (EWSR1, FUS) that would suggest alternative diagnoses require reliable molecular platform availability during business hours. Monitor molecular platforms at 1-minute intervals during business hours.
Surgical platforms coordinate wide resection in anatomically variable locations. Preoperative imaging characterizing soft tissue extent, surgical templating for endoprosthetic or reconstructive approach in extremity, pelvic, or spinal locations, and operative documentation require platform availability throughout the operative period. Monitor surgical platforms at 1-minute intervals during operative sessions.
What to Monitor on a Epithelioid Osteosarcoma Tech Platform
Pathology, Immunohistochemistry, and Diagnosis Confirmation
Monitor biopsy H&E histomorphologic records (epithelioid polygonal cells with eosinophilic cytoplasm and the critical identification of lace-like osteoid production confirming osteoblastic differentiation despite epithelioid morphology), SATB2 immunohistochemistry records (the most sensitive and specific osteoblast lineage marker, positive nuclear staining confirming osteosarcoma diagnosis in the context of epithelioid morphology), broad exclusionary immunophenotypic panel records including keratin (AE1/AE3, CAM5.2, CK7, CK20, CK5/6), CD31, ERG, CD34, PAX8, TTF-1, GATA3, INSM1, p40, osteocalcin, alkaline phosphatase, S100, SOX9, SMA, and CD68 — the comprehensive panel that excludes metastatic carcinoma, epithelioid angiosarcoma, epithelioid hemangioendothelioma, and other epithelioid bone lesions — SATB2 FISH or copy number assessment records for molecular confirmation in ambiguous cases, intraoperative frozen section records, neoadjuvant chemotherapy response grading (Huvos grade) on resection specimens, resection margin assessment, and tumor board pathology-radiology correlation records at 1-minute intervals during business hours. Alert immediately — immunohistochemistry platform failures during SATB2 result review in a case where polygonal epithelioid cells with focal keratin positivity are present delay the definitive confirmation of osteosarcoma versus metastatic carcinoma at the precise moment when the medical oncologist is waiting for SATB2 results before initiating MAP protocol neoadjuvant chemotherapy versus platinum/taxane carcinoma therapy, where the wrong treatment pathway initiated because of platform unavailability results in weeks of inappropriate chemotherapy and tumor progression before corrective diagnosis is established.
Medical Oncology and MAP Protocol Chemotherapy
Monitor MAP protocol cycle scheduling and pharmacy preparation records (high-dose methotrexate, cisplatin, doxorubicin), serum methotrexate level records at 24, 48, and 72 hours post-infusion, leucovorin rescue scheduling and dose escalation records (standard versus escalated rescue based on methotrexate clearance curve at each time point), creatinine clearance documentation before each cisplatin cycle, echocardiographic ejection fraction records for doxorubicin cumulative cardiotoxicity monitoring, cisplatin ototoxicity audiometric monitoring records, complete blood count and dose modification documentation, MAP protocol cycle response assessment imaging records, neoadjuvant versus adjuvant cycle documentation, and stem cell collection and high-dose chemotherapy records for programs using consolidation at 1-minute intervals during infusion sessions. Alert immediately — MAP protocol platform failures during high-dose methotrexate infusion with active leucovorin rescue scheduling disrupt the serum methotrexate level workflow where delayed 48-hour level documentation delays escalated leucovorin rescue initiation and creates risk of severe and potentially fatal methotrexate toxicity in a young patient with epithelioid osteosarcoma.
Next-Generation Sequencing and Molecular Diagnostics
Monitor NGS panel ordering and laboratory processing records (comprehensive genomic profiling identifying copy number alterations typical of osteosarcoma — complex high-level amplifications and deletions without a single defining translocation — and excluding EWSR1 or FUS rearrangements that would indicate Ewing sarcoma or myoepithelial carcinoma), potentially actionable alteration identification records (CDK4 amplification, MDM2 amplification, BRCA1/2 mutations, and other targetable alterations identified in osteosarcoma NGS series), RNA sequencing records for fusion exclusion, tumor mutational burden and microsatellite instability assessment records for immunotherapy eligibility evaluation, molecular turnaround time records, and second opinion consultation at reference bone sarcoma pathology centers for diagnostically ambiguous cases during business hours. Alert immediately — NGS platform failures during molecular result review delay the exclusion of alternative diagnoses in an ambiguous epithelioid bone lesion where the treatment oncologist requires both SATB2 immunohistochemical confirmation and NGS-based molecular exclusion before committing to MAP protocol neoadjuvant chemotherapy in a case where the clinical and imaging features initially suggested metastatic carcinoma.
Surgical Planning and Wide Resection
Monitor preoperative staging records (CT chest for pulmonary metastasis, CT pelvis/abdomen for pelvic primary staging, MRI for local intraosseous and extraosseous extent defining wide resection margins), surgical approach and implant selection records (endoprosthetic reconstruction for appendicular skeleton; custom saddle prosthesis or iliosacral reconstruction for pelvic disease; vertebral body replacement for spinal disease), neoadjuvant response assessment imaging records (post-chemotherapy MRI comparing soft tissue extent and bone involvement), preoperative templating records, intraoperative navigation records for complex pelvic or spinal resections, intraoperative frozen section margin records confirming clear osteosarcoma margins, endoprosthetic implant ordering and sterilization records, and reconstructive surgery documentation at 1-minute intervals during operative sessions. Alert immediately — surgical planning platform failures during wide resection of an epithelioid osteosarcoma in the pelvis eliminate access to preoperative MRI defining the neurovascular proximity and the intraoperative navigation records confirming the osteotomy levels, creating direct risk of inadequate surgical margins or neurovascular injury in an anatomically complex location.
Post-treatment Surveillance and Long-Term Follow-Up
Monitor serial MRI local site surveillance scheduling (every 3 months for years 1–2, every 6 months for years 3–5 post-resection), CT chest surveillance scheduling for pulmonary metastasis detection, plain radiograph surveillance for endoprosthetic integrity, imaging result integration and comparison with prior studies, tumor board documentation for suspicious local or pulmonary findings, CT-guided biopsy or resection scheduling for confirmed recurrence, pulmonary metastasectomy referral records, and NGS repeat profiling records for resistant relapsed disease during business hours. Alert on sustained failures — surveillance platform outages delay detection of pulmonary metastasis in a patient whose early oligometastatic pulmonary relapse may remain amenable to surgical metastasectomy.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Epithelioid osteosarcoma programs coordinate across orthopedic oncology, medical oncology, immunohistochemistry and pathology, molecular diagnostics and NGS, musculoskeletal radiology, reconstructive orthopedic surgery, and thoracic surgery for metastasectomy — authentication failures simultaneously block every team member whose platform access is required to execute the diagnostic workup, MAP protocol chemotherapy, NGS review, surgical planning, and surveillance imaging.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, chemotherapy management systems, immunohistochemistry reporting platforms, molecular diagnostic systems, surgical planning platforms, and surveillance imaging platforms. Certificate errors disrupt the diagnostic, chemotherapy coordination, NGS communication, surgical planning, and surveillance workflows of epithelioid osteosarcoma management.
HIPAA and Oncology Data Privacy Considerations
Epithelioid osteosarcoma technology platforms handle sensitive PHI including comprehensive immunohistochemical panel results documenting SATB2 positivity and the broad carcinoma exclusion workup, NGS reports with potentially actionable molecular alterations, MAP protocol chemotherapy administration records with high-dose methotrexate level monitoring and leucovorin rescue scheduling, anatomically complex surgical resection operative records, and serial surveillance imaging records. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing the SATB2 immunohistochemistry and NGS molecular results — where the diagnostic determination of epithelioid osteosarcoma versus metastatic carcinoma versus epithelioid angiosarcoma based on immunophenotypic and molecular data determines the entire treatment pathway — and for platforms managing MAP protocol chemotherapy administration timing records, both privacy and availability standards must reflect the sensitivity of oncologic diagnostic and treatment data and the clinical consequences of platform unavailability at the moment of diagnostic result communication or chemotherapy safety monitoring. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for bone sarcoma programs managing epithelioid osteosarcoma's intersection of complex immunohistochemistry, molecular diagnostics, intensive chemotherapy, complex surgical oncology, and long-term surveillance PHI.
Alerting Strategy for Epithelioid Osteosarcoma Tech Platforms
Immediate alerting during chemotherapy infusion: MAP protocol platforms, high-dose methotrexate and leucovorin rescue scheduling, serum methotrexate level monitoring, cisplatin and doxorubicin administration, and echocardiographic and audiometric monitoring. These cannot fail during active MAP infusion without creating direct patient safety risk.
Immediate alerting during operative sessions: Surgical planning platforms, intraoperative navigation for complex pelvic or spinal resections, intraoperative frozen section, endoprosthetic templating records, and operative documentation. These cannot fail during wide resection and reconstructive surgery without direct surgical consequence.
Immediate business-hours alert: SATB2 immunohistochemistry reporting, comprehensive exclusionary immunophenotypic panel, NGS molecular diagnostics, pathology reporting, staging imaging, and tumor board review. Alert the moment these fail during active diagnostic or treatment-planning encounters.
Sustained-failure alert (10–15 minutes): Post-treatment local MRI surveillance, CT chest scheduling, and endoprosthetic integrity monitoring platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms epithelioid osteosarcoma platform availability from the geographies where high-volume bone sarcoma programs with SATB2 immunohistochemistry expertise, comprehensive NGS molecular diagnostic capability, MAP protocol chemotherapy expertise, and complex anatomic resection and reconstruction capability concentrate.
Status Page for Epithelioid Osteosarcoma Care Team Communication
A real-time status page gives medical oncologists managing MAP neoadjuvant chemotherapy cycles, clinical pharmacists monitoring serum methotrexate levels and leucovorin rescue timing, musculoskeletal pathologists finalizing SATB2 results and the comprehensive carcinoma exclusion panel, molecular diagnostics teams reporting NGS findings, musculoskeletal radiologists characterizing the epithelioid osteosarcoma soft tissue extent on MRI, orthopedic oncologists planning wide resection approach, and surveillance coordinators scheduling serial MRI and CT chest immediate platform visibility without requiring inbound IT support contact. During an immunohistochemistry platform outage when a musculoskeletal pathologist must finalize SATB2 immunostaining results in a case where an oncology team is waiting to determine whether to initiate MAP protocol chemotherapy for epithelioid osteosarcoma or platinum/taxane therapy for metastatic carcinoma, a status page enables immediate communication of platform downtime and activation of reference pathology consultation procedures without waiting for IT status updates.
Include the status page URL in MAP chemotherapy emergency downtime procedures, immunohistochemistry laboratory emergency contingency procedures, NGS communication downtime procedures, surgical planning contingency protocols, and surveillance imaging fallback workflows.
Vigilmon Setup for Epithelioid Osteosarcoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | MAP protocol / methotrexate + leucovorin rescue (infusion hours) | 1 min | Slack + PagerDuty (infusion hours) | | Serum methotrexate level monitoring (24/48/72 hr) | 1 min | Slack + PagerDuty (infusion hours) | | Cisplatin / doxorubicin / echocardiography / audiometry | 1 min | Slack + PagerDuty (clinical hours) | | SATB2 immunohistochemistry / exclusion panel (IHC platform) | 1 min | Slack + PagerDuty (business hours) | | Pathology reporting / H&E osteoid characterization | 1 min | Slack + PagerDuty (business hours) | | NGS / comprehensive genomic profiling | 1 min | Slack + PagerDuty (business hours) | | Staging imaging / CT, MRI characterization (clinical hours) | 1 min | Slack + PagerDuty (clinical hours) | | Surgical planning / complex resection templating (operative hours) | 1 min | Slack + PagerDuty (surgical hours) | | Intraoperative navigation / frozen section / fluoroscopy | 1 min | Slack + PagerDuty (surgical hours) | | Neoadjuvant response imaging / tumor board review | 2 min | Slack (business hours) | | MRI local surveillance / CT chest scheduling | 2 min | Slack (business hours) | | Endoprosthetic implant integrity / plain radiograph surveillance | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure MAP protocol platforms with immediate alerting during infusion windows — including methotrexate, serum level monitoring, leucovorin rescue scheduling, cisplatin, and doxorubicin administration
- Add SATB2 immunohistochemistry and comprehensive exclusionary immunophenotypic panel platforms with immediate business-hours alerting
- Configure pathology reporting and H&E osteoid characterization with immediate business-hours alerting
- Add NGS and comprehensive genomic profiling platforms with immediate business-hours alerting
- Configure staging imaging platforms (CT, MRI) with immediate clinical-hours alerting
- Add surgical planning and complex resection templating platforms with immediate alerting during operative windows
- Configure intraoperative navigation, frozen section, and fluoroscopy platforms with immediate surgical-hours alerting
- Add neoadjuvant response imaging and tumor board review with sustained-failure alerting
- Configure local MRI surveillance and CT chest scheduling with sustained-failure alerting
- Add endoprosthetic implant integrity and plain radiograph surveillance with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, immunohistochemistry, molecular diagnostic, chemotherapy, surgical, and surveillance domains
- Add the status page URL to MAP chemotherapy emergency downtime procedures, immunohistochemistry contingency procedures, NGS communication downtime procedures, surgical contingency protocols, and surveillance fallback workflows
Conclusion
Epithelioid osteosarcoma technology platforms are embedded in clinical decisions where pathology and immunohistochemistry platform availability during the critical SATB2 result review — where the musculoskeletal pathologist has identified large polygonal cells with abundant eosinophilic cytoplasm in a bone biopsy from a 28-year-old patient, where the initial H&E review raises the question of metastatic renal cell carcinoma versus epithelioid osteosarcoma based on the cytomorphology, where the comprehensive immunophenotypic panel has been run and the SATB2 immunostaining result documenting diffuse strong nuclear positivity in the epithelioid tumor cells is now the single piece of information that determines whether the oncology team initiates MAP protocol neoadjuvant chemotherapy for osteosarcoma (the correct treatment for a young adult with epithelioid osteosarcoma) or pursues additional carcinoma workup including CT chest-abdomen-pelvis for an occult primary with bone metastasis (the incorrect pathway that delays osteosarcoma-specific treatment by weeks to months while the tumor progresses), and where this immunostaining result must be communicated from the immunohistochemistry laboratory to the pathologist and from the pathologist to the tumor board before the treatment decision is made — cannot be disrupted by platform unavailability at the precise moment when a SATB2-positive result on an epithelioid bone lesion is sitting unread in a laboratory information system that is inaccessible because the platform is down; where MAP protocol platform availability during high-dose methotrexate infusion for a young adult with epithelioid osteosarcoma who has now been correctly diagnosed and has begun neoadjuvant chemotherapy — where the clinical pharmacist must review the serum methotrexate level at 48 hours post-infusion to determine whether the level is following the expected clearance curve or whether delayed clearance is emerging, triggering dose-escalated leucovorin rescue to prevent the severe and potentially fatal toxicity of accumulated high-dose methotrexate including mucositis, myelosuppression, acute kidney injury, and hepatotoxicity, and where the leucovorin rescue dose escalation must be documented in the chemotherapy management platform and communicated to the infusion nursing team before the rescue window closes — cannot be interrupted by a platform outage during the 48-hour post-infusion serum level monitoring window that is the most time-critical operational moment of the entire MAP protocol neoadjuvant cycle; and where surgical planning platform availability on the morning before wide resection of a pelvic epithelioid osteosarcoma — where the orthopedic oncologist must access the post-neoadjuvant-chemotherapy MRI to confirm the soft tissue extent of the tumor relative to the external iliac vessels and sciatic nerve before finalizing the resection approach, where the intraoperative navigation system must be loaded with the preoperative CT for osteotomy level planning, and where the custom saddle prosthesis procurement records must be confirmed before the implant is opened on the operative field — cannot be disrupted by a platform outage on the morning of the most complex reconstructive operation in the patient's treatment course. A pathology and immunohistochemistry platform that fails when the SATB2 result is waiting to determine whether MAP protocol or carcinoma chemotherapy begins, a chemotherapy platform inaccessible when the pharmacist is monitoring 48-hour serum methotrexate clearance for leucovorin rescue adequacy, a surgical planning platform unavailable when the orthopedic oncologist is finalizing the pelvic resection approach the morning of surgery — these are not IT incidents. They are clinical disruptions in the management of a rare high-grade osteosarcoma variant where diagnostic accuracy prevents inappropriate carcinoma treatment, chemotherapy platform availability prevents methotrexate toxicity, and surgical planning precision enables the curative-intent wide resection that is the cornerstone of long-term survival.
Uptime monitoring gives epithelioid osteosarcoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to bone sarcoma surgery programs, medical oncology services, immunohistochemistry and molecular pathology laboratories, and compliance auditors that platform operational reliability matches the diagnostic precision demands, chemotherapy safety requirements, complex surgical planning needs, and long-term surveillance obligations of modern epithelioid osteosarcoma management.
Start monitoring your epithelioid osteosarcoma care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #epithelioid #osteosarcoma #bonesarcoma #SATB2 #immunohistochemistry #carcinoma #differential #MAPprotocol #methotrexate #leucovorin #cisplatin #doxorubicin #NGS #moleculardiagnostics #limbsalvage #pelvis #musculoskeletaloncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre